NeoImmuneTech, Inc. (NIT) is an immunotherapy-focused biotech company developing T cell production factor, "IL-7-hyFc (Hyleukin)," for the prevention and treatment of lymphopenia.

Founded in January 2014, NIT is developing Hyleukin, its novel T cell production factor, for the prevention and treatment of lymphopenia as a monotherapy and extending its application to combination therapies to treat human papillomavirus (HPV) derived cancers and other various cancers.

Hyleukin is a fusion protein consisting of recombinant engineered interleukin-7 (IL-7) and hyFc. HyFc is a platform technology used to construct a long-acting Fc fusion protein, which was licensed to NIT from Genexine, Inc. under Genexine’s patents. Hyleukin is expected to provide sustainable therapeutic levels of fully functional IL-7 to the reproduction of T cell population. NIT anticipates that Hyleukin will provide IL-7 with prolonged half-life, few side effects, and cost effective production compared to the IL-7 produced in CHO cells. Hyleukin's technical advantages are shown as the following:

  • 1) Enhancing in vivo T cell activity by extending half-life
  • 2) Reconstituting T cell systems that are damaged after chemotherapy
  • 3) Activating mucosal T cell immunity by targeting mucosal T cell zone

Key milestones are to obtain clinical POC data for lymphopenia until 2017.

To install the latest Internet Explorer